Eledon Pharmaceuticals Exchanges Common Stock for Pre-Funded Warrants with Major Investor
ELDN sits 20% above its 52-week low of $1.35 on light trading volume (0.3× avg).
Summary
Eledon Pharmaceuticals entered an agreement to exchange 4.2 million common shares for pre-funded warrants with Coastlands Capital Partners LP, a move that temporarily reduces outstanding common stock and allows the investor to manage beneficial ownership.
Key Events · Financing and Capital Events · ELDN
-
Exchange Agreement Executed
Eledon Pharmaceuticals, Inc. entered into an exchange agreement with Coastlands Capital Partners LP on December 30, 2025.
-
Common Stock Exchanged for Warrants
Coastlands Capital Partners LP exchanged 4,203,764 shares of common stock for pre-funded warrants to purchase an equal number of common shares.
-
Beneficial Ownership Management
The pre-funded warrants include a beneficial ownership limitation, typically 4.99%, which can be increased to 19.99% with prior notice, allowing the holder to manage their reported ownership stake.
-
Pre-Funded Nature
The warrants have a nominal exercise price of $0.001 per share, as the aggregate exercise price was pre-funded to the company prior to the initial exercise date.
Analysis · ELDN · Life Sciences
This transaction represents a strategic capital structure adjustment rather than a traditional capital raise or dilutive offering. Eledon Pharmaceuticals is effectively reducing its outstanding common share count by 4.2 million shares in exchange for pre-funded warrants. This could temporarily enhance per-share metrics. For Coastlands Capital Partners LP, this structure allows them to maintain a significant economic interest in the company while managing their beneficial ownership percentage, potentially staying below certain reporting thresholds. The 'pre-funded' nature indicates the company has already received the capital for these shares, and the warrants will eventually convert back to common stock at a nominal exercise price. Investors should note this reclassification of a substantial equity stake and its implications for capital structure and investor relations.
At the time of this filing, ELDN was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.6M. The 52-week trading range was $1.35 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.